Research programme: chimeric antigen receptor T cell therapy - HaemaLogiX

Drug Profile

Research programme: chimeric antigen receptor T cell therapy - HaemaLogiX

Alternative Names: CAR-T cell therapy - HaemaLogiX; KMA.CAR-T; LMA.CAR-T

Latest Information Update: 25 Aug 2015

Price : $50

At a glance

  • Originator HaemaLogiX
  • Developer HaemaLogiX; Westmead Institute for Medical Research
  • Class CAR-T cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 08 May 2015 Haemalogix files for patent protection for KMA and LMA CAR-T cells
  • 08 May 2015 Preclinical trials in Multiple myeloma in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top